<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36505947</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2732-494X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Antimicrobial stewardship &amp; healthcare epidemiology : ASHE</Title><ISOAbbreviation>Antimicrob Steward Healthc Epidemiol</ISOAbbreviation></Journal><ArticleTitle>The effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post-COVID-19 conditions: A systematic literature review and meta-analysis.</ArticleTitle><Pagination><StartPage>e192</StartPage><MedlinePgn>e192</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e192</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1017/ash.2022.336</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Although multiple studies have revealed that coronavirus disease 2019 (COVID-19) vaccines can reduce COVID-19-related outcomes, little is known about their impact on post-COVID-19 conditions. We performed a systematic literature review and meta-analysis on the effectiveness of COVID-19 vaccination against post-COVID-19 conditions (ie, long COVID).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We searched PubMed, CINAHL, EMBASE, Cochrane Central Register of Controlled Trials, Scopus, and Web of Science from December 1, 2019, to April 27, 2022, for studies evaluating COVID-19 vaccine effectiveness against post-COVID-19 conditions among individuals who received at least 1 dose of Pfizer/BioNTech, Moderna, AstraZeneca, or Janssen vaccine. A post-COVID-19 condition was defined as any symptom that was present 3 or more weeks after having COVID-19. Editorials, commentaries, reviews, study protocols, and studies in the pediatric population were excluded. We calculated the pooled diagnostic odds ratios (DORs) for post-COVID-19 conditions between vaccinated and unvaccinated individuals. Vaccine effectiveness was estimated as 100% &#xd7; (1 - DOR).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In total, 10 studies with 1,600,830 individuals evaluated the effect of vaccination on post-COVID-19 conditions, of which 6 studies were included in the meta-analysis. The pooled DOR for post-COVID-19 conditions among individuals vaccinated with at least 1 dose was 0.708 (95% confidence interval (CI), 0.692-0.725) with an estimated vaccine effectiveness of 29.2% (95% CI, 27.5%-30.8%). The vaccine effectiveness was 35.3% (95% CI, 32.3%-38.1%) among those who received the COVID-19 vaccine before having COVID-19, and 27.4% (95% CI, 25.4%-29.3%) among those who received it after having COVID-19.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">COVID-19 vaccination both before and after having COVID-19 significantly decreased post-COVID-19 conditions for the circulating variants during the study period although vaccine effectiveness was low.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marra</LastName><ForeName>Alexandre R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0002-7577-7688</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade Israelita de Ci&#xea;ncias da Sa&#xfa;de Albert Einstein, Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Access &amp; Delivery Research &amp; Evaluation (CADRE), Iowa City Veterans' Affairs Health Care System, Iowa City, Iowa, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Takaaki</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-4751-6859</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Access &amp; Delivery Research &amp; Evaluation (CADRE), Iowa City Veterans' Affairs Health Care System, Iowa City, Iowa, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsuhaibani</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, King Faisal Specialist Hospital &amp; Research Centre, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7167-270X</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Access &amp; Delivery Research &amp; Evaluation (CADRE), Iowa City Veterans' Affairs Health Care System, Iowa City, Iowa, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tholany</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4415-4573</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perencevich</LastName><ForeName>Eli</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Access &amp; Delivery Research &amp; Evaluation (CADRE), Iowa City Veterans' Affairs Health Care System, Iowa City, Iowa, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maezato</LastName><ForeName>Aline Miho</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Faculdade Israelita de Ci&#xea;ncias da Sa&#xfa;de Albert Einstein, Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricardo</LastName><ForeName>Victoria Catharina Volpe</ForeName><Initials>VCV</Initials><AffiliationInfo><Affiliation>Faculdade Israelita de Ci&#xea;ncias da Sa&#xfa;de Albert Einstein, Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salinas</LastName><ForeName>Jorge L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Stanford University, Stanford, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edmond</LastName><ForeName>Michael B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>West Virginia University School of Medicine, Morgantown, West Virginia, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzo</LastName><ForeName>Luiz Vicente</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Faculdade Israelita de Ci&#xea;ncias da Sa&#xfa;de Albert Einstein, Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Antimicrob Steward Healthc Epidemiol</MedlineTA><NlmUniqueID>9918266096106676</NlmUniqueID><ISSNLinking>2732-494X</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>12</Day><Hour>11</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36505947</ArticleId><ArticleId IdType="pmc">PMC9726631</ArticleId><ArticleId IdType="doi">10.1017/ash.2022.336</ArticleId><ArticleId IdType="pii">S2732494X22003369</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post COVID-19 condition or long COVID: a meta-analysis and systematic review. J Infect Dis 2022;226:1593&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings&#x2014;Barnstable County, Massachusetts, July 2021. Morbid Mortal Wkly Rep 2021;70:1059&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8367314</ArticleId><ArticleId IdType="pubmed">34351882</ArticleId></ArticleIdList></Reference><Reference><Citation>Glatman-Freedman A, Hershkovitz Y, Kaufman Z, Dichtiar R, Keinan-Boker L, Bromberg M. Effectiveness of BNT162b2 vaccine in adolescents during outbreak of SARS-CoV-2 delta variant infection, Israel, 2021. Emerg Infect Dis 2021;27:2919&#x2013;2922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8544958</ArticleId><ArticleId IdType="pubmed">34570694</ArticleId></ArticleIdList></Reference><Reference><Citation>Chodick G, Tene L, Rotem RS, et al. The effectiveness of the two-dose BNT162b2 vaccine: analysis of real-world data. Clin Infect Dis 2022;74:472&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8240867</ArticleId><ArticleId IdType="pubmed">33999127</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Rio C, Malani PN, Omer SB. Confronting the delta variant of SARS-CoV-2, summer 2021. JAMA 2021;326:1001&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pubmed">34406361</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin-Rector A, Firestein L, McGibbon E, et al. Reduced odds of SARS-CoV-2 reinfection after vaccination among New York City adults, July&#x2013;November 2021. Clin Infect Dis 2022. doi: 10.1093/cid/ciac380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9129172</ArticleId><ArticleId IdType="pubmed">35594552</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383:2603&#x2013;2615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med 2021;385:585&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314739</ArticleId><ArticleId IdType="pubmed">34289274</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ (Clin Res) 2021;373:n1088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8116636</ArticleId><ArticleId IdType="pubmed">33985964</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine efficacy, effectiveness and protection. World Health Organization website. https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection. Published 2021. Accessed October 13, 2022.</Citation></Reference><Reference><Citation>Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 vaccine against omicron variant in South Africa. N Engl J Med 2022;386:494&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757569</ArticleId><ArticleId IdType="pubmed">34965358</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N, Stowe J, Kirsebom F, et al. COVID-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med 2022;386:1532&#x2013;1546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908811</ArticleId><ArticleId IdType="pubmed">35249272</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Milne A, Samms E, Stadon L, Maskell NA, Hamilton FW. Symptoms After COVID-19 vaccination in patients with persistent symptoms after acute infection: a case series. Ann Intern Med 2021;174:1334&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8252827</ArticleId><ArticleId IdType="pubmed">34029484</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. Do vaccines protect from long COVID? Lancet Respir Med 2022;10:e30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8776281</ArticleId><ArticleId IdType="pubmed">35065716</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Center for Immunization and Respiratory Diseases (NCIRD) Division of Viral Diseases. Long COVID or post-COVID conditions. Centers for Disease Control and Prevention website.https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. Published 2022. Accessed May 20, 2022.</Citation></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008&#x2013;2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Commun Health 1998;52:377&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1756728</ArticleId><ArticleId IdType="pubmed">9764259</ArticleId></ArticleIdList></Reference><Reference><Citation>Alderson PGS HJ, editors. Assessment of study quality. In: Cochrane Reviewer&#x2019;s Handbook version 4.2.3. Chichester, UK: John Wiley &amp; Sons; 2004.</Citation></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis 2022;22:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M, De Martino M, Palese A, et al. Post&#x2013;COVID-19 syndrome and humoral response association after one year in vaccinated and unvaccinated patients. Clin Microbiol Infect 2022;28:1397&#x2013;1398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9279256</ArticleId><ArticleId IdType="pubmed">35842022</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuodi P, Gorelik Y, Zayyad H, et al. Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients infected between March 2020 and November 2021. NPJ Vaccines 2022;7:101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9411827</ArticleId><ArticleId IdType="pubmed">36028498</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun 2022;103:154&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon MA, Luginbuhl RD, Parker R. Reduced incidence of long-COVID symptoms related to administration of COVID-19 vaccines both before COVID-19 diagnosis and up to 12 weeks after. medRxiv 2021. doi: 10.1101/2021.11.17.21263608.</Citation></Reference><Reference><Citation>Arnold D, Milne A, Samms E, Stadon L, Maskell N, Hamilton F. Are vaccines safe in patients with Long COVID? A prospective observational study. medRxiv 2021. doi: 10.1101/2021.03.11.21253225.</Citation></Reference><Reference><Citation>
Doebler P, Holling H, Sousa-Pinto B. Meta-analysis of diagnostic accuracy with mada. R Project Organization website. https://cran.r-project.org/web/packages/mada/vignettes/mada.pdf. Published 2017. Accessed November 21, 2022.</Citation></Reference><Reference><Citation>Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pubmed">16168343</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto M, Ohl ME, Schweizer ML, Perencevich EN. Accuracy of administrative code data for the surveillance of healthcare-associated infections: a systematic review and meta-analysis. Clin Infect Dis 2014;58:688&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">24218103</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherlinger M, Pijnenburg L, Chatelus E, et al. Effect of SARS-CoV-2 vaccination on symptoms from post-acute sequelae of COVID-19: results from the nationwide VAXILONG study. Vaccines (Basel) 2021;10:46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8781023</ArticleId><ArticleId IdType="pubmed">35062706</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaskandan H, Nimmo A, Savino M, et al. Burnout and long COVID among the UK nephrology workforce: results from a national survey investigating the impact of COVID-19 on working lives. Clin Kidney J 2022;15:517&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8754810</ArticleId><ArticleId IdType="pubmed">35198158</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V-T, Perrodeau &#xc9;, Saldanha J, Pane I, Ravaud P. Efficacy of COVID-19 vaccination on the symptoms of patients with long COVID: a target trial emulation using data from the ComPaRe e-cohort in France. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9978748</ArticleId><ArticleId IdType="pubmed">36910458</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisnivesky JP, Govindarajulu U, Bagiella E, et al. Association of vaccination with the persistence of post-COVID symptoms. J Gen Intern Med 2022;37:1748&#x2013;1753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8906626</ArticleId><ArticleId IdType="pubmed">35266128</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Li X, Gu X, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med 2022;10:863&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Network Open 2021;4:e2128568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>
Coronavirus disease (COVID-19): post&#x2013;COVID-19 condition. World Health Organization website. https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition. Accessed May 21, 2022.</Citation></Reference><Reference><Citation>Gerussi V, Peghin M, Palese A, et al. Vaccine hesitancy among Italian patients recovered from COVID-19 infection towards influenza and SARS-Cov-2 vaccination. Vaccines 2021;9:172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7922251</ArticleId><ArticleId IdType="pubmed">33670661</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris AD, Lautenbach E, Perencevich E. A systematic review of quasi-experimental study designs in the fields of infection control and antibiotic resistance. Clin Infect Dis 2005;41:77&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">15937766</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>